Healthy With Hard and/or Lumpy Stools
Conditions
Keywords
oligosaccharides
Brief summary
In the present randomised double blind controlled study, we will study the effects of a oligosaccharides vs a placebo on the change in stool consistency and stool frequency in children with hard or lumpy stools.
Detailed description
Firm, hard or lumpy stools can be problematic for young children and might come as a precursor of functional constipation in childhood. The cause of harder stools in childhood is incompletely understood. But it is likely that harder stools in childhood are linked to among others withholding behaviour of stools and a low fibre intake. As hard stools may precede functional constipation, the aim of the study is to investigate the effect of a prebiotic fiber versus a placebo on defecation parameters in healthy children with hard or lumpy stools. We hypothesize that consumption of a prebiotic fiber results in softer stools.
Interventions
OTHERoligosaccharides
1 dose a day of oligosaccharides or placebo
Sponsors
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
FrieslandCampina, Amersfoort, The Netherlands
Wageningen University and Research
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Parallel study with two arms of 13 weeks in total per participant
Eligibility
Sex/Gender
ALL
Age
1 Years to 3 Years
Healthy volunteers
Yes
Inclusion criteria
* Written informed consent * aged 1-4 years * Hard and/or firm stools as scored by a stool questionnaire
Exclusion criteria
* Children that meet the Rome IV criteria for functional constipation * Children who suffer from any other GI complaints, known structural GI abnormalities, or previous GI surgery * Any condition that would make it unsafe for the child to participate. * Children with clinically significant cardiac, vascular, liver, pulmonary, psychiatric disorders, severe renal insufficiency, human immunodeficiency virus, acquired immunodeficiency syndrome, hepatitis B or C or known abnormalities of haematology, urinalysis, or blood biochemistry, as checked by the inclusion questionnaire. * Children who are allergic to cow's milk or fish * Use of antibiotics or other medicines or food supplements, and breast milkfeeding, which can influence defecation and gut microbiota 4 weeks prior to the study * Children that participate in another clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Stool consistency | Stool consistency will be measured at different time points during a study period of 13 weeks. | Change in stool consistency measured by the a stool questionnaire; 5 points stool scale from 1 hard to 5 watery (modified Bristol Stool Form Scale) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Stool frequency in number of cases (%) | These outcome measures will be measured at different time point during a study period of 13 weeks. | Stool frequency - number of times a child has stools a day as reported in a diary.by a stool questionnaire |
| Stool consistency in number of cases (%) | These outcome measures will be measured at different time point during a study period of 13 weeks. | Stool consistency - % of stools in a certain stool scale score as measured via a 5 point stool scale |
Countries
Netherlands
Contacts
Primary ContactClara Belzer, PhD
Backup ContactCarrie Wegh, MSc
Outcome results
None listed